# US 2010/0062978 A1 · Method for inhibiting signal transduction, signal transduction inhibitor to be used therein and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0062978 A1
- Document ID: US20100062978A1
- Status: Published application
- Kind: A1
- Application number: 12/294,347
- Filed: 2007-03-23
- Published: 2010-03-11
- Earliest claimed: 2006-03-24
- Assignees: The University of Tokyo; Tokyo Medical University; National University Corporation Tokyo Medical and Dental University
- Inventors: Noriko Gotoh; Masahiko Kuroda; Nobuo Tsuchida
- Web page: https://patentgrep.com/patent/US20100062978A1

## CPC

- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61P 35/00: Antineoplastic agents
- C07K 14/47: from mammals
- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- G01N 2474/20: Immunohistochemistry assay
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- Y10S 435/968: High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by erbB1 or erbB2 in human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2β. The above-described polypeptide may be introduced directly into cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since erbB1 and erbB2 are involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.

## Claims

### Claim 1

A method for inhibiting signaling which comprises
inhibiting activation of a signaling pathway in a human cell, wherein:
said signaling pathway is mediated by erbB1 in the human cell; and
said activation of the signaling pathway is inhibited by at least one polypeptide selected from the group consisted of the following (A1), (A2), (B1) and (B2):
(A1): a polypeptide comprising an amino acid sequence comprising the 1st-the 185th region in the amino acid sequence shown in SEQ ID NO: 1;
(A2): a polypeptide comprising an amino acid sequence in which one or several amino acid residues are deleted, replaced or added in the amino acid sequence of said (A1), and having a function equivalent to PTB domain of human FRS2β;
(B1): a polypeptide comprising an amino acid sequence comprising the 237th-the 252nd region in the amino acid sequence shown in SEQ ID NO: 1; and
(B2): a polypeptide comprising an amino acid sequence in which one or several amino acid residues are deleted, replaced or added in the amino acid sequence of said (B1), and having a function of binding with human ERK2.

### Claim 2 (depends on 1)

The method for inhibiting signaling according to claim 1, wherein:
said method comprises
administering a signaling inhibitor comprising a nucleic acid into the human cell;
said nucleic acid encodes for said polypeptide; and
said nucleic acid expresses said polypeptide in the cell.

### Claim 3 (depends on 2)

The method for inhibiting signaling according to claim 2, wherein said nucleic acid is at least one nucleic acid selected from the group consisted of the following (a1), (a2), (b1) and (b2):
(a1): a nucleic acid comprising a nucleotide sequence comprising the 1st-the 555th region of the nucleotide sequence shown in SEQ ID NO: 2;
(a2): a nucleic acid comprising a nucleotide sequence in which one or several nucleotides are deleted, replaced or added in the nucleotide sequence of said (a1), and encoding for a polypeptide having a function equivalent to PTB domain of human FRS2β;
(b1): a nucleic acid comprising a nucleotide sequence comprising the 709th-the 756th region of the nucleotide sequence shown in SEQ ID NO: 2; and
(b2): a nucleic acid comprising a nucleotide sequence in which one or several nucleotides are deleted, replaced or added in the nucleotide sequence of said (b1), and encoding for a polypeptide having a function of binding with human ERK2.

### Claim 4 (depends on 3)

The method for inhibiting signaling according to claim 3, wherein said nucleic acid (a1) is a nucleic acid comprising the nucleotide sequence of the 1st-the 555th in the nucleotide sequence shown in SEQ ID NO: 2, and said nucleic acid (b1) is a nucleic acid comprising the nucleotide sequence of the 709th-the 756th in the nucleotide sequence shown in SEQ ID NO: 2.

### Claim 5 (depends on 3)

The method for inhibiting signaling according to claim 3, wherein the nucleic acids of said (a1) and (b1) are human FRS2β gene comprising the nucleotide sequence shown in SEQ ID NO: 2.

### Claim 6 (depends on 3)

The method for inhibiting signaling according to claim 3, wherein said signaling inhibitor comprises at least one of the nucleic acids of said (a1) and (a2) and at least one of the nucleic acids of said (b1) and (b2).

### Claim 7 (depends on 3)

The method for inhibiting signaling according to claim 3, wherein said signaling inhibitor comprises a chimeric nucleic acid comprising at least one of the nucleic acids of said (a1) and (a2) and at least one of the nucleic acids of said (b1) and (b2).

### Claim 8 (depends on 2)

The method for inhibiting signaling according to claim 2, wherein said signaling inhibitor further comprises a vector and said nucleic acid is linked to said vector.

### Claim 9 (depends on 1)

The method for inhibiting signaling according to claim 1, wherein said method comprises
administering a signaling inhibitor comprising said polypeptide into human cell.

### Claim 10 (depends on 1)

The method for inhibiting signaling according to claim 1, wherein said human cell is at least one cancer cell selected from the group consisting of breast cancer, ovarian cancer, gastric cancer, bladder cancer, oral cancer, esophageal cancer, brain tumor and non-small cell lung cancer.

### Claim 11

A signaling inhibitor inhibiting activation of a signaling pathway, wherein:
said signaling pathway is mediated by erbB1 in a human cell;
said inhibitor comprises a nucleic acid;
said nucleic acid is at least one nucleic acid selected from the group consisted of the following (a1), (a2), (b1) and (b2):
(a1): a nucleic acid comprising a nucleotide sequence comprising the 1st-the 555th region of the nucleotide sequence shown in SEQ ID NO: 2;
(a2): a nucleic acid comprising a nucleotide sequence in which one or several nucleotides are deleted, replaced or added in said (a1), and encoding for a polypeptide having a function equivalent to PTB domain of human FRS2β;
(b1): a nucleic acid comprising a nucleotide sequence comprising the 709th-the 756th region of the nucleotide sequence shown in SEQ ID NO: 2;
(b2): a nucleic acid comprising a nucleotide sequence in which one or several nucleotides are deleted, replaced or added in said (b1), and encoding for a polypeptide having a function of binding with human ERK2; and
said nucleic acid encodes a polypeptide expressed in the cell.

### Claim 12 (depends on 11)

The signaling inhibitor according to claim 11, wherein said nucleic acid (a1) is a nucleic acid comprising a nucleotide sequence of the 1st-the 555th in the nucleotide sequence shown in SEQ ID NO: 2, and said nucleic acid (b1) is a nucleic acid comprising a nucleotide sequence of the 709th-the 756th in the nucleotide sequence shown in SEQ ID NO: 2.

### Claim 13 (depends on 11)

The signaling inhibitor according to claim 11, wherein said nucleic acids of (a1) and (b1) are human FRS2β gene comprising the nucleotide sequence shown in SEQ ID NO: 2.

### Claim 14 (depends on 11)

The signaling inhibitor according to claim 11, wherein said signaling inhibitor comprises at least one of the nucleic acids of said (a1) and (a2) and at least one of the nucleic acids of said (b1) and (b2).

### Claim 15 (depends on 11)

The signaling inhibitor according to claim 11, wherein said signaling inhibitor comprises a chimeric nucleic acid comprising at least one of the nucleic acids of said (a1) and (a2) and at least one of the nucleic acids of said (b1) and (b2).

### Claim 16 (depends on 11)

The signaling inhibitor according to claim 11, wherein said signaling inhibitor further comprises a vector and said nucleic acid is linked to said vector.

### Claim 17

A signaling inhibitor inhibiting activation of signaling pathway, wherein:
said signaling pathway is mediated by erbB1 in a human cell;
said inhibitor comprises a polypeptide;
said polypeptide is at least one polypeptide selected from the group consisted of the following (A1), (A2), (B1) and (B2):
(A1): a polypeptide comprising an amino acid sequence comprising the 1st-the 185th region in the amino acid sequence shown in SEQ ID NO: 1;
(A2): a polypeptide comprising an amino acid sequence in which one or several amino acid residues are deleted, replaced or added in said (A1), and having a function equivalent to PTB domain of human FRS2β;
(B1): a polypeptide comprising an amino acid sequence comprising the 237th-the 252nd region in the amino acid sequence shown in SEQ ID NO: 1; and
(B2): a polypeptide comprising an amino acid sequence in which one or several amino acid residues are deleted, replaced or added in said (B1), and having a function of binding with human ERK2.

### Claim 18

An anticancer drug for human use comprising at least one signaling inhibitor selected from
a nucleic acid selected from the group consisting of:
(a1): a nucleic acid comprising a nucleotide sequence comprising the 1st-the 555th region of the nucleotide sequence shown in SEQ ID NO: 2;
(a2): a nucleic acid comprising a nucleotide sequence in which one or several nucleotides are deleted, replaced or added in said (a1), and encoding for a polypeptide having a function equivalent to PTB domain of human FRS2β;
(b1): a nucleic acid comprising a nucleotide sequence comprising the 709th-the 756th region of the nucleotide sequence shown in SEQ ID NO: 2;
(b2): a nucleic acid comprising a nucleotide sequence in which one or several nucleotides are deleted, replaced or added in said (b1), and encoding for a polypeptide having a function of binding with human ERK2; wherein
said nucleic acid encodes a polypeptide expressed in the cell; or
a polypeptide selected from the group consisting of:
(A1): a polypeptide comprising an amino acid sequence comprising the 1st-the 185th region in the amino acid sequence shown in SEQ ID NO: 1;
(A2): a polypeptide comprising an amino acid sequence in which one or several amino acid residues are deleted, replaced or added in said (A1), and having a function equivalent to PTB domain of human FRS2β;
(B1): a polypeptide comprising an amino acid sequence comprising the 237th-the 252nd region in the amino acid sequence shown in SEQ ID NO: 1; and
(B2): a polypeptide comprising an amino acid sequence in which one or several amino acid residues are deleted, replaced or added in said (B1), and having a function of binding with human ERK2.

### Claim 19 (depends on 18)

The anticancer drug according to claim 18, wherein said anticancer drug is an anticancer drug against at least one cancer cell selected from the group consisted of breast cancer, ovarian cancer, gastric cancer, bladder cancer, oral cancer, esophageal cancer, brain tumor, and non-small cell lung cancer.

### Claim 20

A cell proliferation inhibitor for human cell comprising at least one signaling inhibitor selected from
a nucleic acid selected from the group consisting of:
(a1): a nucleic acid comprising a nucleotide sequence comprising the 1st-the 555th region of the nucleotide sequence shown in SEQ ID NO: 2;
(a2): a nucleic acid comprising a nucleotide sequence in which one or several nucleotides are deleted, replaced or added in said (a1), and encoding for a polypeptide having a function equivalent to PTB domain of human FRS2β;
(b1): a nucleic acid comprising a nucleotide sequence comprising the 709th-the 756th region of the nucleotide sequence shown in SEQ ID NO: 2;
(b2): a nucleic acid comprising a nucleotide sequence in which one or several nucleotides are deleted, replaced or added in said (b1), and encoding for a polypeptide having a function of binding with human ERK2; wherein
said nucleic acid encodes a polypeptide expressed in the cell; or
a polypeptide selected from the group consisting of:
(A1): a polypeptide comprising an amino acid sequence comprising the 1st-the 185th region in the amino acid sequence shown in SEQ ID NO: 1;
(A2): a polypeptide comprising an amino acid sequence in which one or several amino acid residues are deleted, replaced or added in said (A1), and having a function equivalent to PTB domain of human FRS2β;
(B1): a polypeptide comprising an amino acid sequence comprising the 237th-the 252nd region in the amino acid sequence shown in SEQ ID NO: 1; and
(B2): a polypeptide comprising an amino acid sequence in which one or several amino acid residues are deleted, replaced or added in said (B1), and having a function of binding with human ERK2.

### Claim 21 (depends on 20)

The cell proliferation inhibitor according to claim 20, wherein said cell proliferation inhibitor is an inhibitor against at least one cancer cell selected from the group consisted of breast cancer, ovarian cancer, gastric cancer, bladder cancer, oral cancer, esophageal cancer, brain tumor, and non-small cell lung cancer.

### Claim at position 22

22-23. (canceled)

### Claim 24

A kit for measuring down-regulation of human FRS2β gene comprising at least one selected from the group consisted of an antibody specific for human FRS2β, a probe specific for human FRS2β gene and a primer specific for human FRS2β gene.

### Claim 25

A method for treating human cancer comprising
administering at least one signaling inhibitor selected from
a nucleic acid selected from the group consisting of:
(a1): a nucleic acid comprising a nucleotide sequence comprising the 1st-the 555th region of the nucleotide sequence shown in SEQ ID NO: 2;
(a2): a nucleic acid comprising a nucleotide sequence in which one or several nucleotides are deleted, replaced or added in said (a1), and encoding for a polypeptide having a function equivalent to PTB domain of human FRS2β;
(b1): a nucleic acid comprising a nucleotide sequence comprising the 709th-the 756th region of the nucleotide sequence shown in SEQ ID NO: 2;
(b2): a nucleic acid comprising a nucleotide sequence in which one or several nucleotides are deleted, replaced or added in said (b1), and encoding for a polypeptide having a function of binding with human ERK2; wherein
said nucleic acid encodes a polypeptide expressed in the cell; or
a polypeptide selected from the group consisting of:
(A1): a polypeptide comprising an amino acid sequence comprising the 1st-the 185th region in the amino acid sequence shown in SEQ ID NO: 1;
(A2): a polypeptide comprising an amino acid sequence in which one or several amino acid residues are deleted, replaced or added in said (A1), and having a function equivalent to PTB domain of human FRS2β;
(B1): a polypeptide comprising an amino acid sequence comprising the 237th-the 252nd region in the amino acid sequence shown in SEQ ID NO: 1; and
(B2): a polypeptide comprising an amino acid sequence in which one or several amino acid residues are deleted, replaced or added in said (B1), and having a function of binding with human ERK2.

### Claim 26 (depends on 25)

The method for treatment according to claim 25, wherein said cancer is at least one cancer selected from the group consisted of breast cancer, ovarian cancer, gastric cancer, bladder cancer, oral cancer, esophageal cancer, brain tumor, and non-small cell lung cancer.

### Claim 27

A method for determining presence of down-regulation of a signaling pathway, wherein:
said signaling pathway is mediated by erbB1 in a human cell; and
said method comprises
detecting at least one of human FRS2β protein and a transcript of human FRS2β gene.

### Claim 28

A method of diagnosis for determining necessity of treatment of a human cancer cell with an anticancer drug, wherein:
said anticancer drug comprises an anti-human erbB1 antibody, and
said method comprises
detecting at least one of human FRS2β protein and a transcript of human FRS2β gene in a human cancer cell.

### Claim at position 28

29-30. (canceled)

### Claim 31 (depends on 1)

The method for inhibiting signaling according to claim 1, wherein said polypeptide is at least one polypeptide of said (A1) and (A2).

### Claim 32

A method of treating a human cell with at least one drug targeting erbB1, comprising:
measuring in a human cancer cell expression of human FRS2β gene;
determining that expression of human FRS2β gene is not down-regulated in the human cancer cell; and
treating the human cancer cell with at least one drug targeting erbB1.

### Claim 33 (depends on 36)

The method of claim 36, wherein expression of human FRS2β gene is measured by
an immunoassay or by measurement of human FRS2β mRNA
